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Edited by Varda RotterAbstract The Epstein-Barr virus (EBV) encoded latent mem-
brane protein 1 (LMP1) plays an important role in the carcino-
genesis of nasopharyngeal carcinoma (NPC). The tumor
suppressor p53 is an important transcription factor. The muta-
tion of the p53 gene is the frequent alteration in most of tumors,
but nearly 100% wild-type p53 gene is found in NPC biopsy.
Here, our study testiﬁed that SV40 T-antigen transformed
nasopharyngeal epithelial cells contained free, wild-type p53.
Moreover, LMP1 regulated p53 both at transcriptional and
translational level. Furthermore, the mechanism of p53 accumu-
lation mediated by LMP1 from post-translational level-phos-
phorylation and ubiquitination were determined. Therefore, the
eﬀects of EBV LMP1 on p53 may potentially contribute to
EBV-associated pathogenesis.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Nasopharyngeal carcinoma (NPC) is the high-frequency
cancer in China, Southeast Asia, some western countries [1].
In contrast to other head and neck cancers, a unique feature
of NPC is its strong association with Epstein-Barr Virus
(EBV). Among the EBV encoded genes, latent membrane pro-
tein 1 (LMP1) is the only one with oncogenic properties [2].
LMP1 can transform established rodent cell lines and alter
the phenotype of both lymphoid and epithelial cells, also it
causes epidermal hyperplasia, lymphomas and papillomatosis
in transgenic mice [3,4]. The tumor suppressor p53 is an impor-
tant transcription factor that evolved in cell cycle arrest, apop-
tosis, DNA repair, or senesce via inducing the diﬀerent subsets
of genes. Meanwhile, the activation of p53 is need to be mod-
iﬁed at post-translational level, including phosphorylation,
ubiquitination and acetylation events, and leads to temporary
growth arrest or apoptosis [5].
Alteration of the p53 gene, such as point mutation, deletion,
or rearrangement, are found in most of the human tumors,*Corresponding authors. Fax: +86 731 4470589.
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leading to tumor formation. Among them, the mutation of the
p53 gene is the frequent alteration in the carcinogenesis of can-
cers [6]. It is reported that the mutations of p53 are found clus-
tered in four ‘‘hot-spot’’ located in exons 5, 7, and 8 within the
DNA-binding domain, which coincide with the four most
highly conserved regions of the gene [7]. Another important
mechanism of p53 inactivation in the tumors is that p53 pro-
tein can form a complex with several diﬀerent DNA tumor
virus genes and produce cell transformation, including the sim-
ian virus 40 large tumor antigen [8], the E1B 55 kDa protein
form adenovirus type 5 [9], and human papilloma virus types
16 and 18 E6 protein [10].
Unlike other human tumors and Burkitt lymphoma, another
EBV-associated malignancy, nearly 100% wild-type p53 gene is
found in NPC [11–13]. Therefore, p53 mutation is an infre-
quent event and maybe has some signiﬁcant role in the patho-
genesis of NPC. EBV infection and the over-expression of p53
are involved in the multi-step process of human nasopharyn-
geal epithelial carcinogenesis [14,15]. p53 over-expression
seemed to occur at an early stage in the development of
NPC and associated with advanced disease stage, poor re-
sponse to therapy [16,17]. But whether p53 has its biological
role in the carcinogenesis of NPC is still disputed.
Using immortalized normal nasopharyngeal epithelial cell
lines will allow us to characterize the functions of EBV gene
in this speciﬁc host environment [18]. Despite that wild-type
p53 existed in most of NPC biopsy were conﬁrmation, how-
ever, p53 mutation in ‘‘hot-spot’’ is frequently observed in cell
lines derived from the primary NPC tumors [19]. So the
immortalized normal nasopharyngeal cell line (SV40 T-antigen
transformed) with no p53 mutation will provide a good model
to study the regulation of EBV to p53 in the carcinogenesis of
NPC. Since the stability of p53 is increased in SV40-trans-
formed cells, we hypothesized that in SV40-transformed naso-
pharyngeal epithelial cell, there existed lot of active, wild-type
p53, not complexed to larger T. Furthermore, the activation of
p53 by LMP1 in this model will be conﬁrmation.2. Methods and materials
2.1. Cell culture, plasmids and reagent
NP69, NP69-pLNSX, NP69-LMP1 cells (NP cells) were propagated
in the deﬁned Kertinocyte-SFM (KSFM, GIBCO, Life Technologies,
Basel, Switzerland) supplemented with growth factors, and maintainedation of European Biochemical Societies.
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transformed line, the characters were described as previous [18]. The
B95.8 cell line (ATCC CRL-1612) was grown in RPMI 1640 culture
medium (GIBCO-BRL) supplemented with 10% feral bovine serum.
The Medium was supplemented with 10 mg/ml streptomycin and
10 IU/ml penicillin. pSG5 and pSG5 B95.8-LMP1 had been previously
described. Eﬀectene Transfection Reagent (QIAGEN Company, Hil-
den, Germany) and Luciferase Assay System were used (Promega cor-
poration, Madison, WI, USA).2.2. RT-PCR
Total RNA was extracted from NP69, NP69-pLNSX and NP69-
LMP1 cells using Trizol solution according to the manufacturers rec-
ommendation (invitrogen). Single-stranded cDNAs were synthesized
by M-MLV reverse transcriptase (invitrogen) and ampliﬁed by PCR.
The primer sequences for the p53 entire coding region (P1/P2) and four
mutant hot-spot regions (SHS01/SHS02, SHS03/SHS04) were de-
scribed previously [13]. For internal control, the actin primer sequences
were (Sence) 5 0-TTCCAGCCTTCCTTCCTGGGG-3 0 and (antisence)
GCTCAGGAGGAGCAAT containing 200 bp in between two prim-
ers with annealing temperature 55 C and 35 PCR cycles.2.3. Immunoblotting analysis
Cells were harvested by centrifugation and resuspended in lysis buf-
fer containing 20 mM HEPES, 350 mM NaCl, 1 mM MgCl2, 0.5 mM
EDTA, 0.5 mM dithiothreitol, 20% glycerol, 1% Nonidet P-40, phos-
phatase inhibitor mixture, and protease inhibitor mixture. Cell pellets
were sonicated brieﬂy and cell debris sedimented by brief centrifuga-
tion at 13000 rpm for 5 min at 4 C. Supernatants were transferred
to fresh tubes, and protein content was determined by the Bradford as-
say (Bio-Rad, USA). For Western analysis, 50 lg of total protein was
loaded onto 8–12% Tris–glycine polyacrylamide gels and subjected to
electrophoresis. Proteins were visualized by ECL chemiluminescence
reagents (Pierce Chemical Co., Rockford, IL, USA) using primary
antibodies speciﬁc for human p53 (SC-126; Santa Cruz, CA, USA),
phospho-p53 Ser20 (SC-18079; Santa Cruz, CA,USA), Ser392 (SC-
7997; Santa Cruz, CA, USA), p21 (SC-756; Santa Cruz, CA, USA),
MDM2 (SC-965; Santa Cruz, CA, USA), phospho-p53 Ser15 (9284),
Thr81 (2676) were from Cellular Signaling Technology (Beverly,
MA), LMP1 (CS 1-4, DAKO) and a-tubulin (Sc-5286), goat anti-rab-
bit IgG-HRP (SC-2004), goat anti-mouse IgG-HRP (SC-2005) and
donkey anti-goat IgG-HRP (SC-2020) were from Santa Cruz (CA,
USA).2.4. Immunoﬂuorescence staining and confocal microscopy
Cells were cultured on glass coverslips. After they were washed with
PBS, cells were ﬁxed with ice methanol for 20 min. To display endo-
genous p53 protein, cells were ﬁrst incubated with p53, and then
reacted with corresponding FITC-conjugated IgG as secondary anti-
body. Cellular nuclear were stained with propidium iodide (PI). p53
and PI were visualized under a confocal microscope (Bio-Rad).2.5. Assay for p53-dependent transcription activity
p53-dependent transcription activity was assayed by using NP cells
line transiently transfect a luciferase reporter gene controlled by p53
DNA binding sequences. Conﬂuent monolayers of the NP cells in
24-well plate were trypsinized. Plates were incubated at 37 C in a
humidiﬁed atmosphere of 5% CO2 until the cells were 80–90% conﬂu-
ent. The cells were extracted with lysis buﬀer RLB (Promega), and
luciferase activity was measured using a luminometer (Promega).
The results were expressed as relative p53 activity.Fig. 1. Immunoblotting analysis of the expression of SV40 T-Ag in
NP69, NP69-pLNSX and NP69-LMP1 cells. a-Tubulin as an internal
control.2.6. Sequential immunoprecipitation
Sequential immunoprecipitation of immunodepleted extracts was
performed in the previous procedure. Aliquotes of the clariﬁed lysate
were reacted for overnight at 4 C with the ﬁrst antibody, T-Ag or
p53 antibody, before addition of protein A-Sepharose beads for an
additional 2 h. Following brief low-speed centrifugation to pellet the
beads, the supernate was reimmunoprecipitated with the T-Ag or
p53 antibody in an identical manner. This precleared extract was then
aliquoted for immunoprecipitation with one of the two remaining anti-bodies. The immunoprecipitated protein were then separated in 8%
SDS–polyacrylamide gels and subjected to electrophoresis. Proteins
were visualized by ECL chemiluminescence reagents.3. Results and discussion
3.1. Free, wild-type p53 in SV40 T-antigen transformed
nasopharyngeal epithelial cells
Firstly, immunoblotting analysis was used to show the
expression of SV40 T-antigen in LMP1 negative and positive
cells. As shown in Fig. 1, LMP1 failed to alter the expression
level of SV40 T-antigen in these cells. Next, p53 that unbound
to T-antigen would be detected by Western analysis of sequen-
tial immunoprecipitation (Fig. 2). After determined that lots of
free p53 existed in NP cell, wild-type or mutant-type p53 were
detected in these cells. As shown in Fig. 3, these cell lines gen-
erated fragments of 1.3 kilobases (kb), the size expected for the
wild-type open reading frame with reverse transcriptase-PCR
(Fig. 3A). Next, fragments of mutation hot-spot regions,
showing the expected sizes of 250 and 272 base pairs (bp)
according to wild-type sequence, were determined (Fig. 3B).
Sequencing data showed that there was at least no point muta-
tion in four ‘‘hot-spot’’ (data not show). Taken together, these
results for the ﬁrst time suggest that there are large amounts of
free, wild-type p53 in SV40 T-antigen transformed nasopha-
ryngeal epithelial cells.
The previous concept consistently considered that SV40 T-
antigen is contributed to tumourigenesis due to continuous
inactivation of p53 [20]. But, the recent report argued the
above studies that p53 is constitutively active in cells trans-
formed with the SV40 T-antigen. These ﬁndings indicated that
activated p53 is unbound to T-antigen in SV40 T-antigen
transformed cells, but are metabolically stable, like p53 in
non-SV40 T-antigen transformed cell [21]. Moreover, DNA
damage could induce p53s activity in SV40 T-antigen trans-
formed cells [22]. Beside with SV 40 T-antigen, in human pap-
illomavirus- transformed cells and adenovirus E1-transformed
cells, basal DNA-damage-inducible p53 functions are also in-
tact [23]. Here, we provide the similar evidences that there
are lots of free p53, unbound to SV40 T-antigen, in SV40 T-
antigen transformed NP cells. This raises the possibility that
transient inactivation of p53 via SV40 T-antigen is responsible
for malignant transformation in some stage of tumorigenesis,
but not permanent inactivation of p53.
Fig. 2. Sequential immunoprecipitation of T-Ag and p53. (A) Extracts from wt T-Ag transformed nasopharyngeal cells propagated at 37 C were
sequential immunoprecipitation. (B) Extracts from wt p53 transformed nasopharyngeal cells propagated at 37 C were sequential immunoprecip-
itation. The immunoprecipitates were then subjected to immunoblotting analysis and probed with T-Ag and p53 monoclonal antibodies.
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Free, wild-type p53 is very sensitive to IR or UV-induced
DNA damages, followed by initiating the expression of
down-stream genes. To conﬁrm intact p53 being in NP cells,
cells were treated with 5 Gy of IR. We collected the cells irra-
diated 3 or 6 h by 5 Gy and analyzed the expression of p53,
MDM2 and p21. As expected, IR induced the accumulation
of p53, MDM2 and p21 at both 3 h and 6 h, which indicated
the activation of wild-type p53 in NP cells. Interestingly, the
levels of p53, MDM2 and p21 induced by LMP1 were less than
the levels initiated by irradiation (Fig. 4A). It is reported that
IR increased the p53 expression levels in wild-type p53 cells,
however, the p53 level remains unchanged in cells with mutant
p53 during the same post-irradiation period [24]. Maybe
T-antigen is a highly multifunctional protein that acts on
tumorigenesis regulation by various know and unknown path-
way, at least inactivation of p53 is only the transient events in
carcinogenesis.Among the post-translational modiﬁcation of p53, phos-
phorylation has been studied most intensively and has been
proposed to play a critical role in the stabilization and activa-
tion of p53. Next, the phosphorylation of p53 in IR treated NP
cell were measured by p53 speciﬁc-phosphorylated antibody.
Our data showed that IR induced the phosphorylation of
p53 at Ser15, Ser20, Ser392 and Thr81, less than that of
LMP1 induced phosphorylation of p53 (Fig. 4B). Besides with
LMP1, Epstein-Barr virus nuclear antigen 1 (EBNA1) [25],
hepatitis C virus core protein [26] and HIV-1 envelop [27] also
can modulate p53 in post-translational level. Furthermore, in
the following study we conﬁrmed that LMP1-induced phos-
phorylation of p53 at Ser15 was directly by ERKs; at Ser20
and Thr81 by JNK, at Ser15 and Ser392 by p38 kinase. The
phosphorylation of p53 was associated with its transcriptional
activity and stability modulated by LMP1 [28]. These data
emphasized that the free, wild-type p53 existed in NP cells
again from IR treatment and post-translational level. SV40
Fig. 3. Expression of p53 mRNA in NP cells. Total RNAs were extracted from NP69, NP69-pLNSX and NP69-LMP1 cells, reversed-transcribed
into cDNAs, and ampliﬁed by PCR using two pairs of primers. DL2000 DNA marker was lane M. Samples of the PCR products were analyzed on
1% agarose gels by using the associated pairs of PCR primers. (A) Lanes 2–4 was from RNA of NP69, NP69-pLNSX and NP69-LMP1, respectively.
P1 and P2 generate 1300 bp fragment, actin primer generate 200 bp fragment. (B) Lanes 1 and 4 were from RNA of NP69, lanes 2 and 5 were from
RNA of NP69-pLNSX, lanes 3 and 6 were from RNA of NP69-LMP1. SH01/SH02 generate the 250 bp fragment (lanes 1, 2 and 3); and SH03/SH04
generate 272 bp fragment (lanes 4, 5 and 6).
Fig. 4. Ionizing radiation (IR)-induced the activation of p53. (A) p53, MDM2 and p21 protein expression in NP69, NP69-pLNSX and NP69-LMP1
cells. (B) The phosphorylation of p53 Ser15, Ser20, Ser392 and Thr81 in NP69, NP69-pLNSX and NP69-LMP1 cells. a-Tubulin protein level was
detected as a loading control.
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genesis of EBV LMP1.
3.3. Activation of p53 regulated by EBV LMP1 in NP cells
As an important transcription factor, p53 executes its func-
tion of transcription factor in the nucleus. To test whether p53
was retained by LMP1 in the nucleus, p53 was immunostained
in SV40 T-antigen transformed cells. As shown in Fig. 5A, in
LMP1 negative cells, p53 mainly located in the nucleus, cyto-plasmic part was also showed the expression of p53. However,
in NP69-LMP1 cells, we observed that cytoplasmic staining of
endogenous wild-type p53 was little. Next, NP cells were
subjected to subcellular fractionation in order to conﬁrm the
nuclear accumulation of p53 induced by LMP1. These data
showed that the cytoplasmic and nuclear levels of p53 were in-
creased mediated by LMP1, and the nuclear p53 level of NP69-
LMP1 cells was more obvious. The purity of the nuclear and
cytoplasmic fractions was veriﬁed by immunoblotting with
Fig. 5. Localization of p53 in NP cells. (A) Cells immunostained with anti-p53 antibody followed by the corresponding FITC-conjugated anti-IgG
secondary antibody to show p53 protein. Simultaneously, the cells were stained with propidium iodide to display the nuclei. (B) The expression of p53
in cytoplasmic and nuclear parts among these cells. Cytoplasmic and nuclear extracts were prepared and immunoblotting analysis of the expression
level of p53. a-Tubulin, nucleolin and actin were used as markers to check the extent of nuclear and cytoplasmic separation.
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(Fig. 5B). These ﬁndings suggest that LMP1 could induce
the nuclear accumulation of p53.
Since the transcriptional activity of p53 is important for p53-
mediated nucleotide excision repair (NER), we investigated
whether EBV LMP1 promote the transcriptional activity of
p53. Reporter containing three consensus p53-binding sites
fused to luciferase gene was transfected into NP cells. In the
presence of LMP1, p53 transactivation activity was increased,
compared to the NP69 and NP69-pLNSX cells (Fig. 6A). Fur-
thermore, the protein expression level of LMP1, p53 and
downstream genes in NP cells were analyzed. The expression
of LMP1 in B95.8 cells, an EBV positive cell line, was as posi-
tive control. Our data showed that LMP1 could increase the
amounts of p53, MDM2 and p21 (Fig. 6B). To better under-
stand how p53 is regulated in LMP1-stressed cells, we mea-
sured the expression of these proteins through transientlytransfected LMP1 to NP69 cells. Immunoblotting revealed
that LMP1 could obviously up-regulate the protein level of
p53, MDM2 and p21, moreover, LMP1 was only expressed
in NP69-pSG5LMP1 cells, which assured the eﬃciency of
transfection (Fig. 6C).
p53 increases MDM2 at the transcriptional level, but
MDM2 suppresses p53 activity at the post-translational level.
MDM2 is an E3 ubiquitin ligase that directs the ubiquitination
of p53 via 26 S proteasome, resulting in the degradation of p53
[29]. In the previous study, the phosphorylation of p53 medi-
ated by LMP1 prevented the interaction of MDM2 and p53
through MAP kinases was conﬁrmed [28]. To evaluate these
observations further, we treated these cells in the presence of
25 lMMG132, which was used to block proteasomal degrada-
tion. Interestingly, in absence of MG132, as Fig. 7 showed
that, LMP1 increased the expression of p53 and the phosphor-
ylation of p53, and in LMP1 negative cells, these proteins
Fig. 6. The eﬀects of LMP1 to p53 at transcriptional level and translational level. (A) p53 dependent transcription activity was measured by the
luciferase assay, and results were expressed as relative p53 activity. b-Gal gene used as a control to normalize the variation in transfection eﬃciencies
among each sample. Data from three independent experiments were averaged and are presented as mean ± S.E. (B) Eﬀects of the expression of LMP1
on p53, MDM2 and p21 expression. (C) The plasmid pSG5-LMP1 was transiently transfected into NP69 cells. The pSG5 empty vector was also
added as blank control. Immunoblotting analysis of p53, MDM2 and p21 in the transfected NP69 cells was shown. a-Tubulin protein level was
detected as a loading control.
Fig. 7. The ubiquitination of p53 regulated by LMP1. (A) MG132 promotes the phosphorylation of p53 and accumulation. Induction of p53
expression and phosphorylation at serine 15, serine 20, serine 392 and threonine 81 in presence or absence MG132. Lysates were prepared from
NP69, NP69-pLNSX and NP69-LMP1 cells, or untreated with the proteasome inhibitor MG132 (Calbiochem) for 6 h prior to harvesting. p53
phosphorylated on speciﬁc serine and threonine residues were analyzed by immunoblotting. a-Tubulin protein was as a loading control. (B) The
relative amount of phosphorylated p53 was calculated as the percent of total p53 using densitometry.
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expression of p53 and phosphorylation of p53 increased obvi-
ously in LMP1 negative cells, as well as in LMP1 positive cells
(Fig. 7). These data demonstrated that lots of p53 degraded
through ubiquitin proteasome system in LMP1 negative NP
cells, while, in LMP1 positive cells, LMP1 augmented the
expression of p53 via inhibiting p53 proteolysis in 26 S protea-
some. This is the ﬁrst time to explain LMP1 regulated p53
through a post-ubiquitination mechanism.
Our previous studies also showed that LMP1 could induce
the accumulation of p53 protein and upregulate its transcrip-
tion activity in p53-mutant NP cells [30]. These results ob-
tained here not only conﬁrm the previously conclusion and
reconcile the discrepant results obtained in the published stud-
ies cited earlier, but also reveal unanticipated complexities in
the function of p53 in the carcinogenesis of NPC [31,32].
In conclusion, these ﬁndings for the ﬁrst time elucidated the
activation of p53 triggered by LMP1 in wild-type p53 NP cells.
Another question that we need to consider is that p53 may has
other function than inducing apoptosis, such as favor for virus
replication and initiating the expression of oncogene, such as
MDM2, in the carcinogenesis of NPC. The exploration of
LMP1 regulated p53 will further deﬁne the role of p53 in the
pathogenesis of NPC.
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